Iradimed Corp. (IRMD) Tops Q2 EPS by 3c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
IRADIMED CORPORATION Announces Second Quarter 2016 Financial Results
July 29, 2016 7:00 AM EDTRevenue grows 29.7% compared to the same quarter last yearReports second quarter 2016 GAAP diluted EPS of $0.19 and non-GAAP diluted EPS of $0.24Increases full year 2016 non-GAAP earnings guidanceSubmits patient vital signs monitor 510(k) application to FDA for review
WINTER SPRINGS, Fla., July 29, 2016 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), the only known provider of non-magnetic intravenous (IV) infusion pump systems that are designed to be safe for use during magnetic resonance imaging (MRI) procedures, today announced financial results for the three and six months ended June 30, 2016.Â
For the second... More
